Remove 2015 Remove Innovation Remove Management Remove Mayo
article thumbnail

Putting Humans at the Center of Health Care Innovation

Harvard Business Review

The healthcare industry has long relied on traditional, linear models of innovation – basic and applied research followed by development and commercialization. An alternative emerging at healthcare institutions worldwide is human-centered design and co-creation, a set of approaches that can accelerate and humanize healthcare innovation.

article thumbnail

The Internet Is Finally Forcing Management to Care About People

Harvard Business Review

The humanist strand of management thinking that celebrates teams and collaboration through respect for customers and workers as human beings has a long and distinguished history. Achieving humanistic management has thus turned out to be a much more intractable problem than most thought leaders expected it to be.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How RFID Technology Improves Hospital Care

Harvard Business Review

When redesigning the new and expanded emergency room at the Mayo Clinic’s Saint Marys Hospital in Rochester, Minnesota, Mayo leaders didn’t just want to add more rooms and square feet. The project was launched in 2013, and the RFID system was rolled out in stages starting in the summer of 2015. Insight Center.

article thumbnail

Giving Patients an Active Role in Their Health Care

Harvard Business Review

And yet, as so many of us know who have attempted to manage our own care or tend to sick family members, the U.S. The average, low-risk patient must follow up on referrals to specialists, fill and manage medications, and comply with physical therapy and other regimes. Innovating for Value in Health Care. Insight Center.

article thumbnail

Price Gouging and the Dangerous New Breed of Pharma Companies

Harvard Business Review

In 1950 two Mayo Clinic researchers were awarded the Nobel Prize in medicine for discovering ACTH, the active ingredient in Acthar. Since its passage in 1983, the ODA has governed approval of drugs for rare diseases and has incentivized pharmaceutical innovation via multiple tax breaks and seven years of market exclusivity.

Price 14